Skip to main content

Advertisement

SpringerLink
Log in

Screening for the lupus anticoagulant

  • From Meetings
  • 2nd International Symposium On Standardization And Quality Control Of Coagulation Tests: Implications For The Clinical Laboratory
  • Published:
Research in Clinic and Laboratory

Summary

The lupus anticoagulant may be defined as an immunoglobulin (IgG, IgM or both) which interferes with one or more of thein vitro phospholipid-dependent tests of coagulation. For many years, lupus anticoagulants were regarded as a laboratory nuisance; consequently, reagents were often selected on the basis of insensitivity to lupus anticoagulants. Recently, lupus anticoagulants have been associated with a variety of clinical conditions including recurrent thromboembolic events (both arterial and venous), obstetrical complications including fetal death and spontaneous abortion, and a variety of hematologic and neurologic complications. As a result, many laboratories are now being asked to identify the presence of lupus anticoagulants in selected patient populations. In addition to assays for lupus anticoagulants, there are immunologic assays designed to detect phospholipid antibodies using solid phase systems (RIA or ELISA). A variety of screening tests have been designed to enhance sensitivity to lupus anticoagulants. Test systems with decreased amounts of phospholipid (phosphatidylserine) appear to be most sensitive to lupus anticoagulants. Of the various tests used, the activated partial thromboplastin time (APTT) appears to be most sensitive. The sensitivity of any screening test system is inversely proportional to the residual platelets in the patient sample. APTT reagents differ widely in their sensitivity to lupus anticoagulants. The dilute Russell viper venom time is also highly dependent on the choice and concentration of phospholipid with respect to its sensitivity. Once an abnormality of a screening test has been identified, it is necessary to prove the abnormal result is due to the presence of an inhibitor. This step in the diagnosis may utilize either mixing studies or plasma agarose gels. The final step in the diagnosis of lupus anticoagulants is the demonstration of phospholipid specificity of the inhibitor. Two approaches have been utilized:1. test systems designed to enhance anticoagulant effect (phospholipid-depleted), and2. test systems with increased or altered phospholipids which will bypass or neutralize the anticoagulant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Alving B. M., Barr C. F.: The dilute phospholipid APTT: evaluation of specificity for antibodies against cardiolipin and phosphatidylserine — Thrombos. Haemostas.58, 391, 1987. (Abstract #1433).

    Google Scholar 

  2. Asherson R. A.: A ‘primary’ antiphospholipid syndrome? — J. Rheumatol.15, 1742, 1988. (Editorial).

    PubMed  CAS  Google Scholar 

  3. Bennett R. E., Calabrese L. H., Lucas F. V., Clough J. D.: The association between anti-DNA antibodies and the lupus anticoagulant — Arthrit. Rheumat.27, 539, 1984. (Abstract).

    Article  Google Scholar 

  4. Bird P.: Coagulation in an agarose gel and its application to the detection and measurement of factor VIII antibodies — Brit. J. Haematol.29, 329, 1975.

    Article  CAS  Google Scholar 

  5. Brandt J. T.: Personal communication.

  6. Brandt J. T., Arkin C. F., Bovill E. G., Rock W. A., Triplett D. A.: Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance: results from the College of American Pathologists survey program — Arch. Pathol. Lab. Med. (In press).

  7. Brandt J. T., Triplett D. A.: Detection of lupus anticoagulants: comparison of three methods of performing the dilute Russell viper venom time (dRVVT) with the APTT — Thrombos. Haemostas.62, 379, 1989. (Abstract #1189).

    Google Scholar 

  8. Brandt J. T., Triplett D. A., Musgrave K., Orr C.: The sensitivity of different coagulation reagents to the presence of lupus anticoagulants — Arch. Pathol. Lab. Med.111, 120, 1987.

    PubMed  CAS  Google Scholar 

  9. Brandt J. T., Wurst A., Iams J.: Comparative sensitivity of APTT, kaolin clotting time (KCT), dilute Russell viper venom time (dRVVT) and antiphospholipid antibodies in detecting patients with recurrent pregnancy loss — Thrombos. Haemostas.62, 297, 1989. (Abstract #955).

    Google Scholar 

  10. Cassidy P. G., Triplett D. A., LaDuca F. M.: Use of the agarose gel method to identify and quantitate factor VIII:C inhibitors — Amer. J. clin. Pathol.83, 697, 1985.

    CAS  Google Scholar 

  11. Cohen A. J., Philips T. M., Kessler C. M.: Circulating coagulation inhibitors in the acquired immunodeficiency syndrome — Ann. intern. Med.104, 175, 1986.

    PubMed  CAS  Google Scholar 

  12. Conley C. L., Hartmann R. C.: A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus — J. clin. Invest.31, 621, 1952.

    Google Scholar 

  13. Duran-Suarez J. R.: Incidence of circulating anticoagulants in a normal population — Acta haematol. (Basel)67, 217, 1982.

    CAS  Google Scholar 

  14. Ewing N. P., Kasper C. K.:In vitro detection of mild inhibitors to factor VIII in hemophilia — Amer. J. clin. Pathol.77, 749, 1982.

    CAS  Google Scholar 

  15. Exner T.: Comparison of two simple tests for the lupus anticoagulants — Amer. J. clin. Pathol.83, 215, 1985.

    CAS  Google Scholar 

  16. Exner T., Rickard K. A., Kronenberg H.: A sensitive test demonstrating lupus anticoagulant and its behavioural patterns — Brit. J. Haematol.40, 143, 1978.

    Article  CAS  Google Scholar 

  17. Feinstein D. I., Rapaport S. I.: Acquired inhibitors of blood coagulation. In:Spaet T. (Ed.): Progress in Hemostasis and Thrombosis. Grune and Stratton, New York, 1972; vol. 1, p. 75.

    Google Scholar 

  18. Forastiero R. R., Cerrato G. S., Falcon C. R., Carreras L. O.: A comparison between coagulation tests used for the detection of lupus anticoagulant — Thrombos. Haemostas.62, 379, 1989. (Abstract #1191).

    Google Scholar 

  19. Gastineau D. A., Kazmier F. J., Nichols W. L., Bowie E. J. W.: Lupus anticoagulants: an analysis of the clinical and laboratory features of 219 cases — Amer. J. Hematol.19, 265, 1985.

    Article  CAS  Google Scholar 

  20. Green D., Hougie C., Kazmier F. J., Lechner K., Mannucci P. M., Rizza C. R., Sultan Y.: Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the ‘lupus’ anticoagulant — Thrombos. Haemostas.49, 144, 1983.

    CAS  Google Scholar 

  21. Haire W. D.: The acquired immunodeficiency syndrome and lupus anticoagulant — J. Amer. med. Ass.252, 3399, 1984.

    Article  Google Scholar 

  22. Harris E. N., Gharavi A. E., Asherson R. A., Hughes G. R. V.: Antiphospholipid antibodies: a review — Europ. J. Rheumatol. Inflammat.7, 5, 1984.

    CAS  Google Scholar 

  23. Harris E. N., Gharavi A. E., Boey M. L., Patel B. M., MacWorth-Young C. G., Loizou S., Hughes G. R. V.: Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus — Lancetii, 1211, 1983.

    Article  Google Scholar 

  24. Harris E. N., Gharavi A. E., Hughes G. R. V.: Antiphospholipid antibodies — Clin. rheumat. Dis.11, 591, 1985.

    CAS  Google Scholar 

  25. Horellou M. H., Aurousseau M. H., Boffa M. C., Conard J., Wiesel M. L., Samama M.: Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients — J. Med.18, 199, 1987.

    PubMed  CAS  Google Scholar 

  26. Hougie C., Bird A. R.: Lupus anticoagulant in pregnancy — Brit. J. Haematol.60, 390, 1985. (Letter).

    Article  Google Scholar 

  27. Hughes G. R. V.: Thrombosis, abortion, cerebral disease and the lupus anticoagulant — Brit. med. J.287, 1088, 1983.

    CAS  Google Scholar 

  28. Johns A. S., Ockelford P. A., Chamley L., Pattison N. S., McKay E. J., Corkill M., Hart H.: Comparison of tests for the lupus anticoagulant and phospholipid antibodies in systemic lupus erythematosus — Thrombos. Haemostas.62, 380, 1989. (Abstract #1192).

    Google Scholar 

  29. Kelsey P. R., Stevenson K. J., Poller L.: The diagnosis of lupus anticoagulants by the activated partial thromboplastin time — the central role of phosphatidylserine — Thrombos. Haemostas.52, 172, 1984.

    CAS  Google Scholar 

  30. Kornberg A., Silber L., Yona R., Kaufman S.: Clinical manifestations and laboratory findings in patients with lupus anticoagulants — Europ. J. Haematol.42, 90, 1989.

    Article  CAS  Google Scholar 

  31. Lazarchick J., Kizer J.: The laboratory diagnosis of lupus anticoagulants — Arch. Pathol. Lab. Med.113, 177, 1989.

    PubMed  CAS  Google Scholar 

  32. Levine S. R., Welch K. M. A.: The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies — Arch. Neurol. (Chic.)44, 876, 1987.

    CAS  Google Scholar 

  33. Liu H. W., Wong K. L., Lin C. K., Wong W. S., Tse P. W. T., Chan G. T. C.: The reappraisal of dilute tissue thromboplastin inhibition test in the diagnosis of lupus anticoagulant — Brit. J. Haematol.72, 229, 1989.

    Article  CAS  Google Scholar 

  34. Lo S. C. L., Oldmeadow M. J., Howard M. A., Firkin B. G.: Comparison of laboratory tests used for identification of the lupus anticoagulant — Amer. J. Hematol.30, 213, 1989.

    Article  CAS  Google Scholar 

  35. Lossing T. S., Kasper C. K., Feinstein D. I.: Detection of factor VIII inhibitors with the partial thromboplastin time — Blood49, 793, 1977.

    PubMed  CAS  Google Scholar 

  36. Lubbe W. F., Liggins G. C.: Role of lupus anticoagulant and autoimmunity in recurrent pregnancy loss — Semin. Reprod. Endocrinol.6, 181, 1988.

    Article  Google Scholar 

  37. Mannucci P. M., Canciani M. T., Mari D., Meucci P.: The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant — Scand. J. Haematol.22, 423, 1979.

    PubMed  CAS  Google Scholar 

  38. Margolius A., Jackson D. P., Ratnoff O. D.: Circulating anticoagulants: a study of 40 cases and a review of the literature — Medicine (Baltimore)40, 145, 1961.

    Google Scholar 

  39. McGlasson D. L., Brey R. L., Strickland D. M., Patterson W. R.: Differences in kaolin-clotting times and platelet counts resulting from variations in specimen processing — Clin. Lab. Sci.2, 109, 1989.

    Google Scholar 

  40. Proctor R. R., Rapaport S. I.: The partial thromboplastin time with kaolin: a simple screening test for first stage clotting factor deficiencies — Amer. J. clin. Pathol.36, 212, 1961.

    CAS  Google Scholar 

  41. Raman S. B. K., Saeed S. M.: Lupus anticoagulant: evaluation of sensitivity of various laboratory tests at different levels of APTT — Amer. J. clin. Pathol.90, 508, 1988. (Abstract).

    Google Scholar 

  42. Rauch J., Tannenbaum M., Tannenbaum H., Ramelson H., Cullis P. R., Tilcock C. P. S., Hope M. J., Janoff A. S.: Hybridoma lupus anticoagulants distinguish between bilayer and nonbilayer phase lipid systems in autoimmunity: experimental and clinical aspects — Ann. N.Y. Acad. Sci.475, 366, 1986.

    Article  CAS  Google Scholar 

  43. Rosner E., Pauzner R., Lusky A., Modan M., Many A.: Detection and quantitative evaluation of lupus circulating anticoagulant activity — Thrombos. Haemostas.57, 144, 1987.

    CAS  Google Scholar 

  44. Rosove M. H., Brewer P. M. C., Runge A., Hirji K.: Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids — Amer. J. Hematol.32, 148, 1989.

    Article  CAS  Google Scholar 

  45. Rosove M. H., Ismail M., Koziol B. J., Runge A., Kasper C. K.: Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations — Blood68, 472, 1986.

    PubMed  CAS  Google Scholar 

  46. Schleider M. A., Nachman R. L., Jaffe E. A., Coleman M.: A clinical study of the lupus anticoagulant — Blood48, 499, 1976.

    PubMed  CAS  Google Scholar 

  47. Shapiro S. S., Thiagarajan P.: Lupus anticoagulants — Progr. Hemostas. Thrombos.6, 263, 1982.

    CAS  Google Scholar 

  48. Stevenson K. J., Easton A. C., Curry A., Thomson J. M., Poller L.: The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure — Thrombos. Haemostas.55, 250, 1986.

    CAS  Google Scholar 

  49. Thiagarajan P., Pengo V., Shapiro S. S.: The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants — Blood68, 869, 1986.

    PubMed  CAS  Google Scholar 

  50. Triplett D. A.: Antiphospholipid antibodies and recurrent pregnancy loss — Amer. J. reprod. Immunol. (In press).

  51. Triplett D. A., Brandt J. T.: Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon — Hematol. Pathol.2, 121, 1988.

    PubMed  CAS  Google Scholar 

  52. Triplett D. A., Brandt J. T., Kaczor D., Schaeffer J.: Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure — Amer. J. clin. Pathol.79, 678, 1983.

    CAS  Google Scholar 

  53. Triplett D. A., Brandt J. T., Maas R. L.: The laboratory heterogeneity of lupus anticoagulants — Arch. Pathol. Lab. Med.109, 946, 1985.

    PubMed  CAS  Google Scholar 

  54. Triplett D. A., Brandt J. T., Musgrave K. A., Orr C. A.: The relationship between lupus anticoagulants and antibodies to phospholipid — J. Amer. med. Ass.259, 550, 1988.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Ball Memorial Hospital, 2401 University Avenue, 47303, Muncie, IN, USA

    Douglas A. Triplett

Authors
  1. Douglas A. Triplett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Triplett, D.A. Screening for the lupus anticoagulant. Res. Clin. Lab. 19, 379–389 (1989). https://doi.org/10.1007/BF02871829

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02871829

Key-words

Search

Navigation